The exceedingly high mortality rates of severe and critical COVID-19 warrant the
identification and evaluation of novel therapies that could potentially mitigate the advanced
disease manifestations. Based on preclinical data from this institution and others, the
investigators hypothesize that PI3K inhibition with duvelisib could potentially quell
aberrant hyperactivtation of the innate immune system, preferentially polarize macrophages,
reduce pulmonary inflammation, and limit viral persistence, thereby improving patient
outcomes.